Related references
Note: Only part of the references are listed.Severe hypercalcemia following denosumab treatment in a juvenile patient
Nokitaka Setsu et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2016)
Critical Hypercalcemia Following Discontinuation of Denosumab Therapy for Metastatic Giant Cell Tumor of Bone
Nathan Gossai et al.
PEDIATRIC BLOOD & CANCER (2015)
The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab
David L. Lacey et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Share Paper
